The benefits of leveraging centralized digital ECGs
Why centralized digital ECGs are now essential for precise, regulator‑ready cardiac safety assessment
Vickas Patel, M.D., Ph.D. – VP and Chief Medical Officer, Cardiology at Clario, part of Thermo Fisher Scientific
Summary
Centralized digital electrocardiograms (ECGs) have become foundational to modern cardiac safety assessment across all phases of clinical development. By replacing site‑level paper records with standardized digital acquisition and centralized expert review, sponsors can improve QT/QTc measurement precision, identify emerging safety signals faster and streamline regulatory submissions from Phase I through NDA.
Key takeaways from this article:
- Paper‑based ECGs lack the resolution required for modern QT/QTc assessment
- Centralized digital ECGs enable faster, expert‑verified safety decisions
- Standardized acquisition reduces site‑ and equipment‑driven variability
- Digital ECG data integrates more efficiently into the Integrated Summary of Safety
Across every phase of a clinical trial, precise and reliable cardiac safety assessment is essential
From first‑in‑human dose escalation through late‑phase confirmatory studies, regulators expect sponsors to characterize potential cardiac risk with accuracy, consistency and traceability before a therapy can advance.
Historically, clinical sites relied on locally stored, paper‑based ECGs. Today, that approach no longer aligns with regulatory expectations or the complexity of modern development programs. Centralized digital ECG management has become the standard, not simply as a technology upgrade, but as a strategic requirement for ensuring data integrity, audit readiness and regulatory confidence.
Regardless of trial phase or sample size, the demand for clean, interpretable ECG data remains constant. Even a small number of missing, imprecise or inconsistently measured ECGs can complicate safety interpretation, delay development timelines or trigger regulatory questions that ripple across a program.
Millisecond‑level precision for thorough QT studies
The gold standard for evaluating cardiac repolarization risk in early development is the ICH E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential guidance.
The limitation of paper ECGs
Measuring QT intervals manually with calipers on paper tracings introduces unavoidable variability. Paper resolution, ink thickness and reader subjectivity make it difficult to reliably detect the small QTc changes emphasized in E14. A 5–10 millisecond shift, often the difference between a manageable signal and a regulatory concern, cannot be measured with sufficient confidence using paper‑based methods.
The digital advantage
Centralized digital ECG systems capture high‑resolution waveforms that support interval measurements with approximately 1–2 millisecond precision. That level of accuracy improves reproducibility across readers and time points, reduces measurement noise and supports credible conclusions about whether a compound presents clinically meaningful QT/QTc risk.
In practical terms, digital precision protects sponsors from two costly outcomes: missing a real signal early, or chasing false positives caused by measurement variability.
Faster identification of emerging safety signals
Phase I studies frequently incorporate conservative stopping rules informed by preclinical or early clinical cardiac signals. In this setting, speed and accuracy directly affect participant safety and escalation decisions.
Delays with local interpretation
When ECGs are reviewed solely at the site on paper, investigators must rely on real‑time visual interpretation. Subtle morphology changes or borderline QTc prolongation can be overlooked, especially under time pressure. If a developing signal is missed, subsequent cohorts may receive higher doses before the risk is fully understood.
Centralized digital review in near real time
With centralized digital capture, ECGs can be uploaded quickly to a central core laboratory where expert cardiologists perform standardized overreads. This creates a tighter feedback loop between acquisition and expert interpretation, often within hours, so escalation decisions are based on verified findings rather than site‑level interpretation alone.
That shift matters most in early development, where the margin for error is small and the cost of a delayed signal can include protocol amendments, additional cohorts or preventable safety events.
In early phase development, ECG data must support rapid, confident decisions. Centralized digital ECGs provide the precision and standardization regulators expect, without slowing the trial.
Vickas Patel, M.D., Ph.D. – VP and Chief Medical Officer, Cardiology at Clario, part of Thermo Fisher Scientific
Reduced variability through digital standardization
Early‑phase trials are often conducted across multiple units, each with its own equipment, workflows and staff. Even within a single site, differences in machines, electrode placement technique or staff training can introduce unwanted variability.
Centralized digital ECG programs address this problem through standardization: consistent acquisition processes, uniform device configurations and harmonized data handling. By reducing site‑ and equipment‑driven noise, sponsors can be more confident that observed changes reflect the drug’s pharmacologic effect rather than inconsistencies in how ECGs were collected.
Built‑in compliance and auditability
Digital ECG platforms also support compliance with 21 CFR Part 11 by maintaining a complete audit trail. Every acquisition, measurement and adjustment is logged, creating transparency and traceability that paper files cannot replicate. That auditability reduces risk during inspections and helps sponsors defend their findings when regulators ask for measurement history and data lineage.
Streamlined integration into the integrated summary of safety
Data generated in Phase I does not exist in isolation. It ultimately contributes to the Integrated Summary of Safety (ISS) within the New Drug Application.
The burden of paper‑to‑digital conversion
Paper ECG workflows typically require manual transcription into electronic datasets for analysis and submission. That process is time consuming and introduces avoidable risk, including transcription errors and reconciliation delays. These issues tend to surface late in development, exactly when timelines are most compressed and rework is most expensive.
Digital continuity from first dose to NDA
Centralized digital ECG data is typically stored in CDISC SDTM‑compliant formats, aligning with FDA expectations from the outset. As a result, ECG datasets can move more efficiently into safety analyses, integrated summaries and submission packages. That continuity reduces conversion burden, minimizes error risk and supports faster, more confident regulatory readiness.
Why centralized digital ECGs matter across development
In early development, the objective is clear: fail fast when risk is unacceptable, or proceed with confidence when it is not.
Centralized digital ECG storage provides the high‑fidelity, standardized data required to support both outcomes.
By moving away from local paper records, sponsors reduce variability, improve patient safety oversight and present regulators with a clear, precise and digitally verifiable picture of a therapy’s cardiac safety profile.
Ultimately, the choice between paper‑based ECGs and centralized digital management is not an administrative preference. It is a decision that directly influences data sensitivity, regulatory confidence and the efficiency of the drug development process.
Written by
Vickas Patel, M.D., Ph.D.
VP and Chief Medical Officer, Cardiology at Clario, part of Thermo Fisher Scientific
FAQs
Why are centralized digital ECGs preferred over paper‑based ECGs in modern clinical trials?
Centralized digital ECGs provide the resolution and consistency required for accurate QT/QTc assessment, which paper‑based ECGs cannot reliably support. Manual measurements on paper introduce variability due to reader subjectivity, paper quality, and limited resolution. Digital ECGs capture high‑fidelity waveforms that enable millisecond‑level precision and reproducible measurements. This precision aligns with current regulatory expectations for cardiac safety evaluation across all trial phases.
How do centralized digital ECGs improve early detection of cardiac safety signals?
Centralized digital ECG systems allow rapid upload and near real‑time review by expert cardiologists at a core laboratory. This standardized overread process helps identify subtle QTc prolongation or morphology changes that may be missed during site‑level visual interpretation. Faster, expert‑verified feedback supports safer dose escalation decisions in early‑phase studies. Early detection reduces the risk of protocol amendments, additional cohorts, or delayed development timelines.
What regulatory and submission advantages do centralized digital ECGs provide?
Centralized digital ECG platforms maintain complete audit trails that support compliance with regulations such as 21 CFR Part 11. ECG data is typically stored in CDISC SDTM‑compliant formats, enabling smoother integration into the Integrated Summary of Safety and regulatory submissions. This digital continuity reduces transcription errors, reconciliation delays, and late‑stage rework. As a result, sponsors can present regulators with transparent, traceable, and submission‑ready cardiac safety data.